43 completed, 39 recruiting, 17 active not recruiting, 16 terminated. 148 Phase 1, 56 Phase 2.
Follow Fulvestrant: new trials by email Literature Review of Fulvestrant trials Research Report on Fulvestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer GDC-4198, Fulvestrant, Letrozole - Advanced or Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Genentech, Inc. | 165 | 2026-12-15 | 2026-11-05 |
| Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors FMC-242, Trastuzumab (or biosimilar), Fulvestrant (or generic) - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Frontier Medicines Corporation | 282 | 2026-12-01 | 2026-11-18 |
| A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer PRT13722, Fulvestrant, Abemaciclib - Breast Cancer, Hormone-receptor-positive Breast Cancer | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 242 | 2026-11-16 | 2026-11-12 |
| A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors PF-08165784, Fulvestrant, Atirmociclib - Advanced Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Pfizer | 268 | 2026-11-09 | 2026-11-18 |
| A Phase 1/2a Study of K-1728 in Advanced Solid Tumors K-1728, Fulvestrant, Palbociclib - Breast Neoplasms, Solid Tumors | Phase 1 / Phase 2 | Recruiting | KymaThera, Inc. | 110 | 2026-10-14 | 2026-11-17 |
| Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males Fulvestrant, Anastrozole (ARIMIDEX™) - Inguinal Hernia Unilateral, Inguinal Hernia Without Obstruction or Gangrene | Phase 1 | Recruiting | Northwestern University | 30 | 2026-10-02 | 2026-11-16 |
| A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers AL58805, AL8326, Eribulin - Endometrial Neoplasms, Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors ATX-898, ATX-898, fulvestrant, ribociclib - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Antares Therapeutics, Inc | 343 | 2026-08-31 | 2026-10-16 |
| A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors LAE118, Fulvestrant, Palbociclib - Patients With Advanced Solid Tumors | Phase 1 | Not yet recruiting | Laekna Limited | 150 | 2026-08-01 | 2026-08-26 |
| Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors ERW316, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-30 | 2026-06-22 | |
| Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer IEV407, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer | Phase 1 | Recruiting | Novartis Pharmaceuticals | 194 | 2026-05-28 | 2026-11-03 |
| Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer Serabelisib, Sapanisertib, Fulvestrant - HR+ HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Faeth Therapeutics | 32 | 2026-04-22 | 2026-11-18 |
| A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer HRS-6208 Capsule, HRS-6209 Capsule, HRS-8080 Tablet - Advanced Unresectable or Metastatic Breast Cancer of Adults | Phase 1 / Phase 2 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 180 | 2026-03-27 | 2026-04-03 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors IDE574, Fulvestrant injection - Cancer | Phase 1 | Recruiting | IDEAYA Biosciences | 155 | 2026-03-17 | 2026-11-05 |
| Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor HLX97, Fulvestrant - Advanced/Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Shanghai Henlius Biotech | 138 | 2026-03-01 | 2026-03-18 |
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer BBI-940, Fulvestrant - Breast Cancer, Metastatic Breast Cancer | Phase 1 | Terminated | Boundless Bio, Inc. | 8 | 2026-02-25 | 2026-08-19 |
| A Study of Single Dose of BL0175 in Postmenopausal Women BL0175, Fulvestrant - Postmenopausal Women | Phase 1 | Not yet recruiting | Shanghai Best-Link Bioscience, LLC | 27 | 2026-01-26 | 2026-01-26 |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors AMXT 1501 Dicaprate, DFMO, Fulvestrant - Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Aminex Therapeutics, Inc. | 92 | 2026-01-26 | 2026-10-22 |
| Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors GVV858, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 205 | 2025-12-29 | 2026-10-29 |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors PF-08032562, Fulvestrant, Cetuximab - Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-) | Phase 1 | Recruiting | Pfizer | 260 | 2025-12-23 | 2026-11-05 |
Showing 20 of 148. Sign in to see all of them.
Breast Neoplasms (96) · Ovarian Neoplasms (12) · Neoplasms (10) · Neoplasm Metastasis (9) · Endometrial Neoplasms (8) · Triple Negative Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Hereditary Sensory and Autonomic Neuropathies (5) · Prostatic Neoplasms (5) · Carcinoma, Ovarian Epithelial (4) · Squamous Cell Carcinoma of Head and Neck (4) · Uterine Cervical Neoplasms (4) · Breast Diseases (3) · Colorectal Neoplasms (3) · Neoplasms by Site (3)
AstraZeneca (8) · Novartis Pharmaceuticals (8) · Eli Lilly and Company (5) · ImmunityBio, Inc. (5) · BeOne Medicines (4) · Memorial Sloan Kettering Cancer Center (4) · Pfizer (4) · Genentech, Inc. (3) · Hoffmann-La Roche (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Mayo Clinic (3) · National Cancer Institute (NCI) (3) · Avenzo Therapeutics, Inc. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Dana-Farber Cancer Institute (2)
United States (101) · China (25) · France (25) · Spain (25) · United Kingdom (20) · Australia (18) · South Korea (14) · Canada (13) · Japan (13) · Italy (12) · Germany (9) · Singapore (7) · Belgium (6) · Denmark (5) · Taiwan (5)
Cynthia Ma (2) · Adrian J Hepner, MD, PhD (1) · Adrienne G Waks, MD (1) · Alison Schram, MD (1) · Amy J Chien, MD (1) · Amy Tiersten, MD (1) · Ana Gonzalez-Angulo, MD, MS (1) · Anja Wiliams (1)
PMID 32385714, PMID 24919854, PMID 25002028, PMID 28540640, PMID 29401002, PMID 30543347, PMID 31235441, PMID 32035020, PMID 32234755, PMID 32619077, PMID 32887722, PMID 33641211, PMID 33660194, PMID 34726887, PMID 35223458, PMID 35235412, PMID 35321427, PMID 35440569, PMID 35671774, PMID 36913051, PMID 36970876, PMID 37488191, PMID 37507802, PMID 37580773, PMID 38439079, PMID 38547892, PMID 38753757, PMID 38937298, PMID 39229468, PMID 39236276, PMID 40627530, PMID 40743286, PMID 41271741, PMID 42061370, PMID 42421507
2016 (6), 2025 (6), 2023 (5), 2017 (4), 2015 (2), UM1CA186704 (2), 2019 (1), N01CM00099 (1), P30CA015083 (1), P30CA091842 (1), R01CA255960 (1), UM1CA186689 (1)